- €35.67bn
- €32.76bn
- $1.23bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 72.07 | ||
| PEG Ratio (f) | 0.79 | ||
| EPS Growth (f) | 972.79% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.84 | ||
| Price to Tang. Book | 9.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 30.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.89% | ||
| Return on Equity | -8.29% | ||
| Operating Margin | -34.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 78.46 | 41.24 | 497.28 | 410.75 | 1,226.32 | 2,121.26 | 3,185.34 | 117.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +658.05 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Directors
- Peter Verhaeghe NEC (62)
- Tim Van Hauwermeiren CEO (49)
- Werner Lanthaler NVC (52)
- Karl Gubitz CFO
- Keith Woods COO (53)
- Hans de Haard CSO (61)
- Arjen Lemmen VBD (36)
- Dirk Beeusaert GCN (57)
- Marc Schorpion DHR (63)
- Wim Parys OTH (61)
- Andria Wilk OTH (48)
- Yvonne Greenstreet NED
- James Daly NID (59)
- Joseph deBethizy NID (70)
- Pamela Klein NID (60)
- Anthony Rosenberg NID (68)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- April 25th, 2008
- Public Since
- July 10th, 2014
- No. of Employees
- 1,148
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Euronext - Brussels- Shares in Issue
- 60,367,650
- Address
- Laarderhoogtweg 25, AMSTERDAM, 1101 EB
- Web
- https://www.argenx.com/
- Phone
- +31 763030
- Auditors
- Deloitte Accountants B.V.
Upcoming Events for ARGX
argenx SE Annual Shareholders Meeting
Q1 2025 argenx SE Earnings Release
Similar to ARGX
Celyad Oncology SA
Euronext - Brussels
Oxurion NV
Euronext - Brussels
Sequana Medical NV
Euronext - Brussels
FAQ
What is the argenx SE share price?
As of Today at 18:20 UTC, shares in argenx SE are trading at €590.80. This share price information is delayed by 15 minutes.
How has the argenx SE share price performed this year?
Shares in argenx SE last closed at €590.80 and the price had moved by +39.18% over the past 365 days. In terms of relative price strength the argenx SE share price has outperformed the FTSE Global All Cap Index by +25.69% over the past year.
What are the analyst and broker recommendations for argenx SE?
The overall consensus recommendation for argenx SE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the argenx SE dividend yield?
argenx SE does not currently pay a dividend.
Does argenx SE pay a dividend?
argenx SE does not currently pay a dividend.
When does argenx SE next pay dividends?
argenx SE does not currently pay a dividend.
How do I buy argenx SE shares?
To buy shares in argenx SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of argenx SE?
As of the previous close price of €590.80, shares in argenx SE had a market capitalisation of €35.67bn.
Where are argenx SE shares listed?
Here are the trading details for argenx SE:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: ARGX
What kind of share is argenx SE?
Based on an overall assessment of its quality, value and momentum argenx SE is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a argenx SE share price forecast for 2024?
The analyst consensus target price for shares in argenx SE is €584.42. That is 1.08% below the last closing price of €590.80.
Analysts covering argenx SE currently have a consensus Earnings Per Share (EPS) forecast of $1.21 for the next financial year.
Find out moreWhat is the trend in the argenx SE share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like argenx SE. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +66.97%.
As of the last closing price of €590.80, shares in argenx SE were trading +36.17% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the argenx SE PE Ratio?
The argenx SE PE ratio based on its reported earnings over the past 12 months is 72.07. The shares last closed at €590.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of argenx SE?
argenx SE's management team is headed by:
- Peter Verhaeghe - NEC
- Tim Van Hauwermeiren - CEO
- Werner Lanthaler - NVC
- Karl Gubitz - CFO
- Keith Woods - COO
- Hans de Haard - CSO
- Arjen Lemmen - VBD
- Dirk Beeusaert - GCN
- Marc Schorpion - DHR
- Wim Parys - OTH
- Andria Wilk - OTH
- Yvonne Greenstreet - NED
- James Daly - NID
- Joseph deBethizy - NID
- Pamela Klein - NID
- Anthony Rosenberg - NID